ResMed Inc. stock gains after RBC upgrade and FY27 growth guidance

Published on 09/17/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ResMed Inc. stock has been supported by Royal Bank of Canada’s upgrade to Outperform and a higher price target as of September 15, 2026. The company now guides fiscal 2027 core revenue up 5% to 7% and core EPS growth of 12% to 14%.

Unbranded CPAP-Gerät mit Atemmaske und Schlauch auf einem Nachttisch im Schlafzimmer — ResMed Inc. (ISIN US7611521078): generisches CPAP-Atemgerät mit Maske und Schlauch steht auf einem Nachttisch, Illustration mit AI erstellt.

ResMed Inc. stock (ISIN US7611521078) has been trading with renewed support after Royal Bank of Canada raised its rating and price target on the shares on September 15, 2026, while management issued fresh guidance pointing to mid-single-digit revenue growth and double-digit earnings expansion for fiscal 2027. As MarketBeat reported on September 15, 2026, RBC shifted its view on ResMed from Sector Perform to Outperform and lifted its price objective from USD 244.00 to USD 262.00, signaling improved confidence in the company’s growth trajectory.MarketBeat

RBC upgrade and higher price target

The key near-term catalyst for ResMed Inc. stock is the rating change at Royal Bank of Canada, which investors received as a positive signal for the medium-term earnings outlook. According to MarketBeat on September 15, 2026, RBC Capital Markets raised its recommendation on ResMed shares from Sector Perform to Outperform and increased its price target from USD 244.00 to USD 262.00, implying a higher expected upside versus the stock’s trading level at that time.MarketBeat As Morningstar’s North American briefing summarized on September 16, 2026, ResMed was among the stocks singled out for an upgrade to Outperform from Sector Perform, highlighting the broker’s view that the company can deliver attractive returns even in a more volatile rate environment.Morningstar

The upgrade and higher target are grounded in ResMed’s recent financial performance. In analysis cited by GuruFocus on September 15, 2026, RBC’s new target of USD 262.00 compared with a contemporaneous ResMed share price around USD 233.06, which GuruFocus described as roughly 12.9 percent below its estimated intrinsic GF Value of USD 267.59 at that point.Ad-hoc-news For shareholders, the combination of an upgraded rating, a higher broker target and a valuation still below that GF Value reference suggests that the market is reassessing ResMed’s earnings power but has not fully priced in the broker’s optimistic scenario.

Fiscal 2027 guidance points to earnings acceleration

Alongside the RBC action, management’s guidance for fiscal 2027 provides the fundamental backbone for the more constructive view on ResMed Inc. stock. According to an Investing.com-based summary dated September 15, 2026, ResMed now expects currency-adjusted core revenue to grow by 5 percent to 7 percent in fiscal 2027 and core earnings per share to increase by 12 percent to 14 percent over the same period.Ad-hoc-news The quantified spread between revenue and earnings growth indicates a planned improvement in margins as scale benefits and product mix changes flow through the income statement.

This outlook builds on the company’s strong finish to the preceding fiscal year. GuruFocus reported on September 15, 2026, that ResMed delivered robust fourth-quarter earnings, which helped justify the new RBC target and supported the case for sustained double-digit EPS expansion over the fiscal 2027 period.Ad-hoc-news For investors, the key takeaway is that management is explicitly guiding to earnings growth almost twice as fast as revenue growth, a profile that tends to support higher valuation multiples when execution is consistent.

Analyst consensus and valuation context

Beyond RBC’s upgrade, ResMed Inc. stock remains widely covered by the analyst community. MarketBeat’s overview as of September 16, 2026, shows a consensus rating of Hold based on 16 analysts, with an average rating score of 2.44 on its four-point scale and no sell ratings.MarketBeat The consensus price target stands at USD 241.69, compared with a high target of USD 300.00 and a low of USD 213.00, implying that RBC’s USD 262.00 objective sits above the average but below the most optimistic view.

For context on valuation and price levels, the same MarketBeat snapshot indicates that ResMed shares were trading around USD 180.26 in mid-September 2026 with a market capitalization of approximately USD 32.93 billion and a trailing price-to-earnings ratio of 21.88, based on trailing twelve-month EPS of USD 10.43.MarketBeat Historically, the shares have traded between a 52-week low near USD 180 and a 52-week high around USD 285 per data cited by Tikr and summarized in recent coverage, placing the current level closer to the lower end of that range and offering room for appreciation if the FY27 guidance is met.Ad-hoc-news

Recent trading and investor perspective

ResMed Inc. stock reacted quickly to the combination of stronger guidance and the RBC upgrade. MarketBeat reported that during trading on September 15, 2026, the shares on the New York Stock Exchange moved up 4.5 percent, reaching an intraday high of USD 233.23 and last trading around USD 232.99, with about 419,842 shares changing hands, a volume roughly 68 percent below the average session turnover of 1,305,453 shares.Ad-hoc-news Per Yahoo Finance data on September 16, 2026, ResMed later traded around USD 228.09 intraday, down 0.59 percent at that moment, showing that some of the initial upgrade-driven gains consolidated but the stock remained well above the 52-week low.Yahoo Finance

For retail investors looking at ResMed Inc. stock as of September 17, 2026, the picture is one of a widely-followed medical technology company with a supportive broker backdrop and clearly stated growth ambitions. The quantified fiscal 2027 targets of 5 percent to 7 percent core revenue growth and 12 percent to 14 percent core EPS growth give a concrete benchmark against which progress can be measured, while the spread between the consensus price target of USD 241.69 and RBC’s higher USD 262.00 objective underlines the debate about how much of that earnings trajectory is already reflected in the share price.MarketBeat

ResMed share price and key data

ResMed Inc. is listed on the New York Stock Exchange under the ticker RMD, and recent price data from Yahoo Finance show the stock trading around USD 228.09 during the session on September 16, 2026, with a modest intraday decline of 0.59 percent at that time.Yahoo Finance With a market capitalization close to USD 32.93 billion and a 52-week trading corridor between roughly USD 180 and USD 285 as described in recent analyses, the shares currently sit below the mid-point of that range, leaving scope for a move higher if the FY27 guidance and broker upgrade translate into sustained earnings momentum.MarketBeat